Discontinued drugs in 2008: Anti-infectives

Expert Opinion on Investigational Drugs

Volumn 19, Issue 1, 2010, Pages 1-21

  Ryder, Neil S ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Aanti infectives; Bacterial infection; Discontinued drugs; Fungal infection; HCV; HIV; HPV; Malaria; Vaccine; West Nile virus

Indexed keywords

4 [4 [5 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4, TRIAZOL 1 YL)PROPYLTHIO] 1,3 DIOXAN 2 YL] 1,3 BUTADIENYL] 3 FLUOROBENZONITIRLE; 7 [3 (1 AMINOCYCLOPROPYL) 1 PYRROLIDINYL] 1 (2 FLUOROCYCLOPROPYL) 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; AUROGRAB; DACART; DC 159A; EPETIRIMOD; FAROPENEM MEDOXOMIL; FRIULIMICIN; FROPENEM; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IDENIX; IMMUNOLOGIC AGENT; INCB 15050; JTK 652; MEDIVIR; MIFEPRISTONE; MIV 150; NESBUVIR; NOVEXEL; NXL 101; OXAZOLIDINONE DERIVATIVE; PAFURAMIDINE; PF 708093; QUINOLONE; TELBIVUDINE; TOLEVAMER; TOMOPENEM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALTORCITABINE; VANCOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADD ON THERAPY; AFRICAN TRYPANOSOMIASIS; BACTERIAL INFECTION; BRONCHITIS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; ENDOCARDITIS; FUNGUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MALARIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYCOSIS; NEPHROTOXICITY; NONHUMAN; OTITIS; PNEUMOCOCCAL INFECTION; PNEUMOCYSTIS PNEUMONIA; PROPHYLAXIS; PROTOZOON; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; SKIN INFECTION; UTERINE CERVIX DYSPLASIA; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

ANIMALS; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASES; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MOLECULAR STRUCTURE; TREATMENT FAILURE;

EID: 72049128109     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903473150     Document Type: Review

References (21)

1. Pharmaprojects database. © Informa UK Ltd; 2009
2. Schafer EA, Narasimhan J, Venkatachari NJ, Ayyavoo V. Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR). Antivir Res 2006;72:224-232
3. Timm A, Enzinger C, Felder E, et al. Genetic stability of recombinant MVA-BN. Vaccine 2006;24:4618-4621
4. Billich A. AIDSVAX VaxGen. Curr Opin Investig Drugs 2004;5:214-221
5. De Bruijne J, Bergmann J, Weegink C, et al. JTK-652 is a novel HCV entry inhibitor: results of a Phase I study evaluating safety, tolerability and antiviral activity in chronic hepatitis C patients. Abstracts of the 44th Annual Meeting of the EASL. Available from: http://www.kenes.com/easl2009/Posters/ Abstract822.htm
6. Toniutto P, Fabris C, Bitetto D, et al. Valopicitabine dihydrochloride: a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs 2007;8:150-158
7. Coelmont L, Paeshuyse J, Windisch MP, et al. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother 2006;50:3444-3446
8. Miller RL, Meng T-C, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect 2008;21:69-87
9. Gettig JP, Crank CW, Philbrick AH. Faropenem medoxomil. Ann Pharmacother 2008;42:80-90
10. Koga T, Masuda N, Kakuta M, et al. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008;52:2849-2854
11. Hoshino K, Inoue K, Murakami Y, et al. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob Agents Chemother 2008;52:65-76
12. Yamamoto T, Dohmae S, Saito K, et al. Molecular characteristics and in vitro susceptibility to antimicrobial agents, including the des-fluoro(6) quinolone DX-619, of Panton-Valentine leucocidin-positive methicillin-resistant Staphylococcus aureus isolates from the community and hospitals. Antimicrob Agents Chemother 2006;50:4077-4086
13. Yanagihara K, Seki M, Izumikawa K, et al. Potency of DX-619, a novel des-F (6)-quinolone, in haematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Int J Antimicrob Agents 2006;28:212-216
14. Black MT, Stachyra T, Platel D, et al. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob Agents Chemother 2008;52:3339-3349
15. Schneider T, Gries K, Josten M, et al. The lipopeptide antibiotic friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. Antimicrob Agents Chemother 2009;53:1610-1618
16. Burnie JP, Matthews RC, Carter T, et al. Identification of an immunodominant ABC transporter in methicillin resistant Staphylococcus aureus infections. Infect Immun 2000;68:1610-1618
17. Rigg GP, Matthews RC, Donohoe MS, et al. Aurograb shows broad spectrum synergy with vancomycin against MRSA and VISA (vancomycin-intermediate) strains of Staphylococcus aureus [abstract no. E-1645]. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif. 2002 Sep 27-30; American Society for Microbiology; 2002
18. Kurtz CB, Cannon EP, Brezzani A, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 2001;45:2340-2347
19. Baines SD, Freeman J, Wilcox MH. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother 2009;53:2202-2204
20. Kamai Y, Harasaki T, Fukuoka T, et al. In vitro and in vivo activities of CS-758 (R-120758), a new triazole antifungal agent. Antimicrob Agents Chemother 2002;46:367-370
21. Cohen J. Surprising AIDS vaccine success praised and pondered. Science 2009;326:26-27